Hypertrophic cardiomyopathy natural history: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(26 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
{{Hypertrophic cardiomyopathy}}
{{Hypertrophic cardiomyopathy}}


'''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org];{{AOEIC}} {{LG}}  
{{CMG}} {{AE}} {{LG}} {{Soroush}} {{Laith}}


==Overview==
==Overview==
The natural history of hypertrophic cardiomyopathy is quite variable. Signs and symptoms range from none, to [[atrial fibrillation]], to [[heart failure]], to embolic [[stroke]], to [[sudden cardiac death]]<ref>Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–33.</ref><ref>Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002;287:1308–20.</ref><ref>Maki S, Ikeda H, Muro A et al. Predictors of sudden cardiac death in
The natural history of hypertrophic cardiomyopathy is quite variable. [[Signs and Symptoms|Signs and symptoms]] range from none, to [[atrial fibrillation]], [[heart failure]], embolic [[stroke]] and [[sudden cardiac death]]. [[Signs and Symptoms|Signs and symptoms]] are quite variable from individual to individual but are also quite variable within a given family (all of whom carry the same [[Mutations|mutation]]).  The disease is quite variable in the timing of its appearance and may appear anywhere from infancy to late in adult life.  About 25% of HCM patients achieve normal longevity. The [[Myosin binding protein C, cardiac|myosin-binding proteins C]] genetic variant carries a good [[prognosis]].  The presence of [[ventricular fibrillation]]/ [[ventricular tachycardia]] carries the poorest [[prognosis]].  The severity of the outflow gradient is also related to [[prognosis]].  Athletes should be screened for HOCM based upon a family history of [[sudden cardiac death]] and a [[Murmurs|murmur]] on [[physical examination]].  [[Electrocardiogram|Electrocardiograms]] and [[echocardiograms]] are not cost-effective [[Screening (medicine)|screening]] tools in this population with a low pre-test probability of disease.
hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774–8.</ref><ref>Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United
States cohort. JAMA 1999;281:650–5.</ref><ref>Maron BJ, Olivotto I, Bellone P et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301–7.</ref>. Signs and symptoms are quite variable from individual to individual but are also quite variable within a given family (all of whom carry the same mutation).  The disease is quite variable in the timing of its appearance and may appear anywhere from infancy to late in adult life.  About 25% of HCM patients achieve normal longevity<ref>Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002;287:1308–20.</ref><ref>Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–5.</ref><ref>Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990;16:821–6.</ref><ref>Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:206–11.</ref>.  The myosin binding proteins C genetic variant carries a good prognosis.  The presence of VT / VF carries the poorest prognosis.  The severity of the outflow gradient is also related to prognosis.  Athletes should be screened for HOCM based upon a family history of [[sudden cardiac death]] and a murmur on physical examination.  Electrocardiograms and echocardiograms are not cost effective screening tools in this population with a low pre-test probability of disease.


==Time and Age Dependent Appearance of Left Ventricular Hypertrophy==
==Natural History, Complications and  Prognosis==
[[Left ventricular hypertrophy]] may be absent in childhood.  It may then appear following the rapid growth of adolescence and may first appear at age 17 to 18<ref>Hagege AA, Dubourg O, Desnos M et al. Familial hypertrophic cardiomyopathy. Cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. Eur Heart J 1998;19:490–9.</ref><ref>Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986;315:610–4.</ref><ref>Spirito P, Maron BJ. Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J
The natural history of hypertrophic cardiomyopathy is quite variable. [[Signs and Symptoms|Signs and symptoms]] range from none, to [[atrial fibrillation]], [[heart failure]], embolic [[stroke]] and [[sudden cardiac death]][[sudden cardiac death|.]]<ref name=":0">Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–33.</ref><ref name=":1">Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002;287:1308–20.</ref><ref name=":2">Maki S, Ikeda H, Muro A et al. Predictors of sudden cardiac death in
Am Coll Cardiol 1987;9:1013–7.</ref>.
hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774–8.</ref><ref name=":3">Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United
States cohort. JAMA 1999;281:650–5.</ref><ref name=":4">Maron BJ, Olivotto I, Bellone P et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301–7.</ref> [[Signs and Symptoms|Signs and symptoms]] are quite variable from individual to individual but are also quite variable within a given family (all of whom carry the same mutation).  The disease is quite variable in the timing of its appearance and may appear anywhere from infancy to late in adult life.  About 25% of HCM patients achieve normal longevity.<ref name=":5">Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002;287:1308–20.</ref><ref name=":6">Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–5.</ref><ref name=":7">Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990;16:821–6.</ref><ref name=":8">Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:206–11.</ref>The [[Myosin binding protein C, cardiac|myosin binding proteins C]] genetic variant carries a good [[prognosis]].  The presence of VT / VF carries the poorest [[prognosis]].  The severity of the outflow gradient is also related to prognosis.  Athletes should be screened for HOCM based upon a family history of [[sudden cardiac death]] and a murmur on physical examination.  [[Electrocardiograms]] and [[echocardiograms]] are not cost-effective screening tools in this population with a low pre-test probability of disease.
 
==Time and Age-Dependent Appearance of Left Ventricular Hypertrophy==
[[Left ventricular hypertrophy]] may be absent in childhood.  It may then appear following the rapid growth of adolescence and may first appear at age 17 to 18.<ref>Hagege AA, Dubourg O, Desnos M et al. Familial hypertrophic cardiomyopathy. Cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. Eur Heart J 1998;19:490–9.</ref><ref>Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986;315:610–4.</ref><ref>Spirito P, Maron BJ. Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J
Am Coll Cardiol 1987;9:1013–7.</ref>


==Sudden Cardiac Death==
==Sudden Cardiac Death==
The incidence of [[sudden cardiac death]] (SCD) in patients with HCM is 2 to 4 percent per year in adults, and a 4 to 6 percent per year in children and adolescents<ref name="pmid11127463">{{cite journal| author=Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A et al.| title=Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 7 | pages= 2212-8 | pmid=11127463 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11127463  }} </ref>.
The incidence of [[sudden cardiac death]] (SCD) in patients with HCM is 2 to 4 percent per year in adults, and a 4 to 6 percent per year in children and adolescents.<ref name="pmid11127463">{{cite journal| author=Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A et al.| title=Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 7 | pages= 2212-8 | pmid=11127463 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11127463  }} </ref>


Among end stage patients with a left ventricular ejection fraction < 50%, the risk of SCD over 5 years may be as high as 47%. In this population, [[syncope]] has been identified as an independent correlate of sudden cardiac death (hazard ratio = 6.15; 95% confidence interval, 2.40-15.75; P < .001)<ref name="pmid21624733">{{cite journal| author=Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H| title=Risk of sudden death in end-stage hypertrophic cardiomyopathy. | journal=J Card Fail | year= 2011 | volume= 17 | issue= 6 | pages= 459-64 | pmid=21624733 | doi=10.1016/j.cardfail.2011.01.015 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21624733  }} </ref>.
Among end stage patients with a left ventricular ejection fraction < 50%, the risk of SCD over 5 years may be as high as 47%. In this population, [[syncope]] has been identified as an independent correlate of sudden cardiac death (hazard ratio = 6.15; 95% confidence interval, 2.40-15.75; P < .001).<ref name="pmid21624733">{{cite journal| author=Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H| title=Risk of sudden death in end-stage hypertrophic cardiomyopathy. | journal=J Card Fail | year= 2011 | volume= 17 | issue= 6 | pages= 459-64 | pmid=21624733 | doi=10.1016/j.cardfail.2011.01.015 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21624733  }} </ref>


A review of 78 patients with HCM who died suddenly or survived a cardiac arrest episode showed that 71 percent were younger than 30 years of age, 54 percent were without functional limitation, and 61 percent were performing sedentary or minimal physical activity at the time of cardiac arrest.
A review of 78 patients with HCM who died suddenly or survived a cardiac arrest episode showed that 71 percent were younger than 30 years of age, 54 percent were without functional limitation, and 61 percent were performing a sedentary or minimal physical activity at the time of the cardiac arrest.


==Predictors of Sudden Cardiac Death==
==Predictors of Sudden Cardiac Death==
There are few predictors of SCD in patients with HCM.
There are few predictors of SCD in patients with HCM.
*Onset of symptoms in childhood <ref>Maron BJ, Tajik AJ, Ruttenberg HD et al. Hypertrophic cardiomyopathy
*Onset of symptoms in childhood. <ref>Maron BJ, Tajik AJ, Ruttenberg HD et al. Hypertrophic cardiomyopathy
in infants. Clinical features and natural history. Circulation 1982; 65:7–17</ref><ref>Skinner JR, Manzoor A, Hayes AM, Joffe HS, Martin RP. A regional study of presentation and outcome of hypertrophic cardiomyopathy
in infants. Clinical features and natural history. Circulation 1982; 65:7–17</ref><ref>Skinner JR, Manzoor A, Hayes AM, Joffe HS, Martin RP. A regional study of presentation and outcome of hypertrophic cardiomyopathy
in infants. Heart 1997;77:229–33.</ref>.
in infants. Heart 1997;77:229–33.</ref>
*A clinical history of spontaneous, sustained monomorphic [[ventricular tachycardia]] (VT) or [[sudden death]] in family members.
*A clinical history of spontaneous, sustained monomorphic [[ventricular tachycardia]] (VT) or [[sudden death]] in family members.
*History of impaired consciousness
*History of impaired consciousness
Line 32: Line 36:
*[[Left ventricular]] wall thickness >30 mm. A recent report of 480 patients showed that left ventricular wall thickness was useful in identifying patients at high risk for [[sudden cardiac death]].  However, [[sudden cardiac death]] can occur in children and adolescents in the absence of [[left ventricular hypertrophy]] as well.
*[[Left ventricular]] wall thickness >30 mm. A recent report of 480 patients showed that left ventricular wall thickness was useful in identifying patients at high risk for [[sudden cardiac death]].  However, [[sudden cardiac death]] can occur in children and adolescents in the absence of [[left ventricular hypertrophy]] as well.


==Prognosis in Survivors of Sudden Cardiac Death==
Survivors of SCD have a poor prognosis.  Event free survival at 1,5 and 10 years was 83, 65 and 53 percent respectively.


== 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy A Report of the American College of Cardiology/American Heart  Association Joint Committee on Clinical Practice Guidelines<ref name="pmid33215931">{{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volume= 142 | issue= 25 | pages= e558-e631 | pmid=33215931 | doi=10.1161/CIR.0000000000000937 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33215931  }}</ref> ==
=== Recommendations for SCD Risk Assessment Referenced studies that support the recommendations are summarized in Online Data Supplement ===
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen" |[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen" |1. In patients with HCM, a comprehensive, systematic noninvasive SCD risk assessment at initial evaluation and every 1 to 2 years thereafter is recommended and should include evaluation of these risk factors1–25 (Figure 1 and Figure 3, Table 7):''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-NR]])''
a.   Personal history of cardiac arrest or sustained ventricular arrhythmias
b.   Personal history of syncope suspected by clinical history to be arrhythmic
c.   Family history in close relative of premature HCM-related sudden death, cardiac arrest, or sustained ventricular arrhythmias
d.   Maximal LV wall thickness, EF, LV apical aneurysm


==2011 ACCF/AHA Guideline Recommendations: SCD Risk Stratification==
e.   NSVT episodes on continuous ambulatory electrocardiographic monitoring
|}


<ref name="pmid22075468">{{cite journal |author=Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW |title=2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=25 |pages=2703–38 |year=2011 |month=December |pmid=22075468 |doi=10.1016/j.jacc.2011.10.825 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)04383-X |accessdate=2011-12-19}}</ref><ref name="pmid22075469">{{cite journal |author=Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW |title=2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=25 |pages=e212–60 |year=2011 |month=December |pmid=22075469 |doi=10.1016/j.jacc.2011.06.011 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02275-3 |accessdate=2011-12-19}}</ref>


{| class="wikitable"
{| class="wikitable"
|-
|-
|colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| colspan="1" style="text-align:center; background:LemonChiffon" |[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIa]]
 
|-
| bgcolor="LemonChiffon" |3. For patients who are ≥ 16 years of age with HCM, it is reasonable to obtain echocardiography-derived left atrial diameter and maximal LVOT gradient to aid in calculating an estimated 5-year sudden death risk that may be useful during shared decision-making for ICD placement''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-NR]])''
|}
 
== ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Hypertrophic Cardiomyopathy (DO NOT EDIT) <ref name="pmid16935995">{{cite journal| author=Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al.| title=ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal=Circulation | year= 2006 | volume= 114 | issue= 10 | pages= e385-484 | pmid=16935995 | doi=10.1161/CIRCULATIONAHA.106.178233 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16935995}}</ref> ==
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class I]]
 
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' ICD therapy should be used for treatment in patients with HCM who have sustained VT and/or VF and who are receiving chronic optimal medical therapy and who have reasonable expectation of survival with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|}


{|class="wikitable"
|-
|-
| bgcolor="LightGreen"|'''1.''' All patients with [[HCM]] should undergo comprehensive SCD risk stratification at initial evaluation to determine the presence of the following: (50,53,55,127,128,386–392)
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIa]]


|-
|-
| bgcolor="LightGreen"|:'''a.''' A personal history for [[ventricular fibrillation]], [[VT|sustained VT]], or [[SCD|SCD events]], including appropriate [[Hypertrophic cardiomyopathy interventional cardiology#Automatic Implantable Cardiac Defibrillator (AICD) placement|ICD therapy]] for ventricular tachyarrhythmias.† ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' ICD implantation can be effective for primary prophylaxis against SCD in patients with HCM who have 1 or more major risk factor (see Table 7) for SCD and who are receiving chronic optimal medical therapy and in patients who have reasonable expectation of survival with a good functional status for more than 1 y. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>


|-
|-
| bgcolor="LightGreen"|:'''b.''' A family history for [[SCD|SCD events]], including appropriate [[Hypertrophic cardiomyopathy interventional cardiology#Automatic Implantable Cardiac Defibrillator (AICD) placement|ICD therapy]] for [[ventricular tachyarrhythmias]].† ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Amiodarone therapy can be effective for treatment in patients with HCM with a history of sustained VT and/or VF when an ICD is not feasible. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|}


{|class="wikitable"
|-
|-
| bgcolor="LightGreen"|:'''c.''' [[Syncope|Unexplained syncope]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIb]]


|-
|-
| bgcolor="LightGreen"|:'''d.''' Documented [[VT|NSVT]] defined as 3 or more beats at greater than or equal to 120 bpm on ambulatory (Holter) ECG. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' EP testing may be considered for risk assessment for SCD in patients with HCM. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>


|-
|-
| bgcolor="LightGreen"|:'''e.''' Maximal LV wall thickness greater than or equal to 30 mm. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Amiodarone may be considered for primary prophylaxis against SCD in patients with HCM who have 1 or more major risk factor for SCD (see Table 7) if ICD implantation is not feasible. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki>
|}
|}


===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]===
==Prognosis in Survivors of Sudden Cardiac Death==
Survivors of SCD have a poor prognosis.  Event free survival at 1, 5, and 10 years was 83, 65, and 53 percent respectively.


'''1.''' It is reasonable to assess blood pressure response during exercise as part of [[SCD]] risk stratification in patients with [[HCM]].(89,127,390) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
== 2011 ACCF/AHA Guideline Recommendations: SCD Risk Stratification ==


'''2.''' SCD risk stratification is reasonable on a periodic basis (every 12 to 24 months) for patients with [[HCM]] who have not undergone ICD implantation but would otherwise be eligible in the event that risk factors are identified (12 to 24 months).''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
<ref name="pmid22075468">{{cite journal |author=Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW |title=2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=25 |pages=2703–38 |year=2011 |month=December |pmid=22075468 |doi=10.1016/j.jacc.2011.10.825 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)04383-X |accessdate=2011-12-19}}</ref><ref name="pmid22075469">{{cite journal |author=Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW |title=2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=25 |pages=e212–60 |year=2011 |month=December |pmid=22075469 |doi=10.1016/j.jacc.2011.06.011 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02275-3 |accessdate=2011-12-19}}</ref>


===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]===
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]


'''1.''' The usefulness of the following potential [[SCD]] risk modifiers is unclear but might be considered in selected patients with [[HCM]] for whom risk remains borderline after documentation of conventional risk factors:
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' All patients with [[HCM]] should undergo comprehensive SCD risk stratification at initial evaluation to determine the presence of the following: <nowiki>"</nowiki>


:'''a.''' [[Hypertrophic cardiomyopathy diagnostic testing#Cardiac MRI|CMR imaging]] with LGE.(184,188) (Level of Evidence: C)
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''a.''' A personal history for [[ventricular fibrillation]], [[VT|sustained VT]], or [[SCD|SCD events]], including appropriate [[Hypertrophic cardiomyopathy interventional cardiology#Automatic Implantable Cardiac Defibrillator (AICD) placement|ICD therapy]] for ventricular tachyarrhythmias.† ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''b.''' A family history for [[SCD|SCD events]], including appropriate [[Hypertrophic cardiomyopathy interventional cardiology#Automatic Implantable Cardiac Defibrillator (AICD) placement|ICD therapy]] for [[ventricular tachyarrhythmias]].† ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''c.''' [[Syncope|Unexplained syncope]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''d.''' Documented [[VT|NSVT]] defined as 3 or more beats at greater than or equal to 120 bpm on ambulatory (Holter) ECG. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>


:'''b.''' Double and compound mutations (i.e., >1). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''e.''' Maximal LV wall thickness greater than or equal to 30 mm. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
|}


:'''c.''' Marked LVOT obstruction.(45,127,143,390) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm)
|-
| bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Invasive electrophysiologic testing as routine [[SCD]] risk stratification for patients with [[HCM]] should not be performed. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|}


===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm)===
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' It is reasonable to assess blood pressure response during exercise as part of [[SCD]] risk stratification in patients with [[HCM]].(89,127,390) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' SCD risk stratification is reasonable on a periodic basis (every 12 to 24 months) for patients with [[HCM]] who have not undergone ICD implantation but would otherwise be eligible in the event that risk factors are identified (12 to 24 months).''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|}


'''1.''' Invasive electrophysiologic testing as routine [[SCD]] risk stratification for patients with [[HCM]] should not be performed. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''}}
{| class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' The usefulness of the following potential [[SCD]] risk modifiers is unclear but might be considered in selected patients with [[HCM]] for whom risk remains borderline after documentation of conventional risk factors:<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''a.''' [[Hypertrophic cardiomyopathy diagnostic testing#Cardiac MRI|CMR imaging]] with LGE.(184,188) (Level of Evidence: C)<nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''b.''' Double and compound mutations (i.e., >1). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''c.''' Marked LVOT obstruction.(45,127,143,390) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
|}


==Guideline Resources==
==Guideline Resources==

Latest revision as of 03:27, 14 December 2022

Hypertrophic Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypertrophic Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypertrophic cardiomyopathy natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypertrophic cardiomyopathy natural history

CDC on Hypertrophic cardiomyopathy natural history

Hypertrophic cardiomyopathy natural history in the news

Blogs on Hypertrophic cardiomyopathy natural history

Directions to Hospitals Treating Hypertrophic cardiomyopathy

Risk calculators and risk factors for Hypertrophic cardiomyopathy natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2] Soroush Seifirad, M.D.[3] Laith Adnan Allaham, M.D.[4]

Overview

The natural history of hypertrophic cardiomyopathy is quite variable. Signs and symptoms range from none, to atrial fibrillation, heart failure, embolic stroke and sudden cardiac death. Signs and symptoms are quite variable from individual to individual but are also quite variable within a given family (all of whom carry the same mutation). The disease is quite variable in the timing of its appearance and may appear anywhere from infancy to late in adult life. About 25% of HCM patients achieve normal longevity. The myosin-binding proteins C genetic variant carries a good prognosis. The presence of ventricular fibrillation/ ventricular tachycardia carries the poorest prognosis. The severity of the outflow gradient is also related to prognosis. Athletes should be screened for HOCM based upon a family history of sudden cardiac death and a murmur on physical examination. Electrocardiograms and echocardiograms are not cost-effective screening tools in this population with a low pre-test probability of disease.

Natural History, Complications and Prognosis

The natural history of hypertrophic cardiomyopathy is quite variable. Signs and symptoms range from none, to atrial fibrillation, heart failure, embolic stroke and sudden cardiac death.[1][2][3][4][5] Signs and symptoms are quite variable from individual to individual but are also quite variable within a given family (all of whom carry the same mutation). The disease is quite variable in the timing of its appearance and may appear anywhere from infancy to late in adult life. About 25% of HCM patients achieve normal longevity.[6][7][8][9]The myosin binding proteins C genetic variant carries a good prognosis. The presence of VT / VF carries the poorest prognosis. The severity of the outflow gradient is also related to prognosis. Athletes should be screened for HOCM based upon a family history of sudden cardiac death and a murmur on physical examination. Electrocardiograms and echocardiograms are not cost-effective screening tools in this population with a low pre-test probability of disease.

Time and Age-Dependent Appearance of Left Ventricular Hypertrophy

Left ventricular hypertrophy may be absent in childhood. It may then appear following the rapid growth of adolescence and may first appear at age 17 to 18.[10][11][12]

Sudden Cardiac Death

The incidence of sudden cardiac death (SCD) in patients with HCM is 2 to 4 percent per year in adults, and a 4 to 6 percent per year in children and adolescents.[13]

Among end stage patients with a left ventricular ejection fraction < 50%, the risk of SCD over 5 years may be as high as 47%. In this population, syncope has been identified as an independent correlate of sudden cardiac death (hazard ratio = 6.15; 95% confidence interval, 2.40-15.75; P < .001).[14]

A review of 78 patients with HCM who died suddenly or survived a cardiac arrest episode showed that 71 percent were younger than 30 years of age, 54 percent were without functional limitation, and 61 percent were performing a sedentary or minimal physical activity at the time of the cardiac arrest.

Predictors of Sudden Cardiac Death

There are few predictors of SCD in patients with HCM.


2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy A Report of the American College of Cardiology/American Heart  Association Joint Committee on Clinical Practice Guidelines[17]

Recommendations for SCD Risk Assessment Referenced studies that support the recommendations are summarized in Online Data Supplement

Class I
1. In patients with HCM, a comprehensive, systematic noninvasive SCD risk assessment at initial evaluation and every 1 to 2 years thereafter is recommended and should include evaluation of these risk factors1–25 (Figure 1 and Figure 3, Table 7):(Level of Evidence: B-NR)

a.   Personal history of cardiac arrest or sustained ventricular arrhythmias

b.   Personal history of syncope suspected by clinical history to be arrhythmic

c.   Family history in close relative of premature HCM-related sudden death, cardiac arrest, or sustained ventricular arrhythmias

d.   Maximal LV wall thickness, EF, LV apical aneurysm

e.   NSVT episodes on continuous ambulatory electrocardiographic monitoring


Class IIa
3. For patients who are ≥ 16 years of age with HCM, it is reasonable to obtain echocardiography-derived left atrial diameter and maximal LVOT gradient to aid in calculating an estimated 5-year sudden death risk that may be useful during shared decision-making for ICD placement(Level of Evidence: B-NR)

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Hypertrophic Cardiomyopathy (DO NOT EDIT) [18]

Class I
"1. ICD therapy should be used for treatment in patients with HCM who have sustained VT and/or VF and who are receiving chronic optimal medical therapy and who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: B)"
Class IIa
"1. ICD implantation can be effective for primary prophylaxis against SCD in patients with HCM who have 1 or more major risk factor (see Table 7) for SCD and who are receiving chronic optimal medical therapy and in patients who have reasonable expectation of survival with a good functional status for more than 1 y. (Level of Evidence: C)"
"2. Amiodarone therapy can be effective for treatment in patients with HCM with a history of sustained VT and/or VF when an ICD is not feasible. (Level of Evidence: C)"
Class IIb
"1. EP testing may be considered for risk assessment for SCD in patients with HCM. (Level of Evidence: C)"
"2. Amiodarone may be considered for primary prophylaxis against SCD in patients with HCM who have 1 or more major risk factor for SCD (see Table 7) if ICD implantation is not feasible. (Level of Evidence: C)"

Prognosis in Survivors of Sudden Cardiac Death

Survivors of SCD have a poor prognosis. Event free survival at 1, 5, and 10 years was 83, 65, and 53 percent respectively.

2011 ACCF/AHA Guideline Recommendations: SCD Risk Stratification

[19][20]

Class I
"1. All patients with HCM should undergo comprehensive SCD risk stratification at initial evaluation to determine the presence of the following: "
"a. A personal history for ventricular fibrillation, sustained VT, or SCD events, including appropriate ICD therapy for ventricular tachyarrhythmias.† (Level of Evidence: B)"
"b. A family history for SCD events, including appropriate ICD therapy for ventricular tachyarrhythmias.† (Level of Evidence: B)"
"c. Unexplained syncope. (Level of Evidence: B)"
"d. Documented NSVT defined as 3 or more beats at greater than or equal to 120 bpm on ambulatory (Holter) ECG. (Level of Evidence: B) "
"e. Maximal LV wall thickness greater than or equal to 30 mm. (Level of Evidence: B) "
Class III (Harm)
"1. Invasive electrophysiologic testing as routine SCD risk stratification for patients with HCM should not be performed. (Level of Evidence: C) "
Class IIa
"1. It is reasonable to assess blood pressure response during exercise as part of SCD risk stratification in patients with HCM.(89,127,390) (Level of Evidence: B) "
"2. SCD risk stratification is reasonable on a periodic basis (every 12 to 24 months) for patients with HCM who have not undergone ICD implantation but would otherwise be eligible in the event that risk factors are identified (12 to 24 months).(Level of Evidence: C) "
Class IIb
"1. The usefulness of the following potential SCD risk modifiers is unclear but might be considered in selected patients with HCM for whom risk remains borderline after documentation of conventional risk factors:"
"a. CMR imaging with LGE.(184,188) (Level of Evidence: C)"
"b. Double and compound mutations (i.e., >1). (Level of Evidence: C) "
"c. Marked LVOT obstruction.(45,127,143,390) (Level of Evidence: B) "

Guideline Resources

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy [19][20]

References

  1. ↑ Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–33.
  2. ↑ Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002;287:1308–20.
  3. ↑ Maki S, Ikeda H, Muro A et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774–8.
  4. ↑ Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–5.
  5. ↑ Maron BJ, Olivotto I, Bellone P et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301–7.
  6. ↑ Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002;287:1308–20.
  7. ↑ Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–5.
  8. ↑ Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990;16:821–6.
  9. ↑ Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:206–11.
  10. ↑ Hagege AA, Dubourg O, Desnos M et al. Familial hypertrophic cardiomyopathy. Cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. Eur Heart J 1998;19:490–9.
  11. ↑ Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986;315:610–4.
  12. ↑ Spirito P, Maron BJ. Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987;9:1013–7.
  13. ↑ Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A; et al. (2000). "Sudden death in hypertrophic cardiomyopathy: identification of high risk patients". J Am Coll Cardiol. 36 (7): 2212–8. PMID 11127463.
  14. ↑ Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H (2011). "Risk of sudden death in end-stage hypertrophic cardiomyopathy". J Card Fail. 17 (6): 459–64. doi:10.1016/j.cardfail.2011.01.015. PMID 21624733.
  15. ↑ Maron BJ, Tajik AJ, Ruttenberg HD et al. Hypertrophic cardiomyopathy in infants. Clinical features and natural history. Circulation 1982; 65:7–17
  16. ↑ Skinner JR, Manzoor A, Hayes AM, Joffe HS, Martin RP. A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants. Heart 1997;77:229–33.
  17. ↑ Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P; et al. (2020). "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 142 (25): e558–e631. doi:10.1161/CIR.0000000000000937. PMID 33215931 Check |pmid= value (help).
  18. ↑ Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M; et al. (2006). "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (10): e385–484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995.
  19. ↑ 19.0 19.1 Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011). "2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Journal of the American College of Cardiology. 58 (25): 2703–38. doi:10.1016/j.jacc.2011.10.825. PMID 22075468. Retrieved 2011-12-19. Unknown parameter |month= ignored (help)
  20. ↑ 20.0 20.1 Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011). "2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Journal of the American College of Cardiology. 58 (25): e212–60. doi:10.1016/j.jacc.2011.06.011. PMID 22075469. Retrieved 2011-12-19. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Hypertrophic_cardiomyopathy_natural_history&oldid=1732161"